Finally listened to rest of call. Some great news paired with some more delays. I think Nasrat shot himself in foot talking about R&D partner so early and M&A. Would have been better for Aug quarter - hindsight is always 20/20.
Financials were solid. Growth all around - revenues, $4M debt paid off, working capital looking fantastic, continued investment in R&D, still only doing one shift and likely still have plenty of capacity in that single shift for more production.
Awesome to hear about how well Lisdex is doing right out of the gate. We didn't get any insight on Q1 revs and knowing we aren't having any major issues wirh API Q1 should be rocking with rich margins as he confirmed today. Other drugs launched continue to grow and gain market share. Nice to see a potential timeframe laid out with investment banker to kick off process once we get more Lisdex time under our belt to help with valuation.
Will Nasrat's (Chairman, CEO & 300M shareholder) share price he has in mind be close to what retail shareholders expect. He carries significant weight in that decision.
We wait - R&D partner & investment firm. Big bummer was to hear about wait on ANDA filing for anticoagulant until Q1 2026 for stabilization study. The end is coming into focus.
Can anyone expound why this ANDA would take significantly longer than others we've submitted? We always have to do stabilization studies for ANDAs.
Market Data 
Markets 
